Therapie mit 177Lu-PSMA-617, Dosimetrie und Nachsorge beim metastasierten kastrations - Resistenten Prostatakarzinom

Wolfgang P. Fendler; Clemens Kratochwil; Hojjat Ahmadzadehfar; Kambiz Rahbar; Richard P. Baum; Matthias Schmidt; Andreas Pfestroff; Ulf Lützen; Vikas Prasad; Alexander Heinzel; Martin Heuschkel; Juri Ruf; Peter Bartenstein; Bernd J. Krause

doi:10.1055/s-0037-1616480

Therapie mit ¹⁷⁷Lu-PSMA-617, Dosimetrie und Nachsorge beim metastasierten kastrations - Resistenten Prostatakarzinom

Translated title of the contribution: ¹⁷⁷Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer

Wolfgang P. Fendler, Clemens Kratochwil, Hojjat Ahmadzadehfar, Kambiz Rahbar, Richard P. Baum, Matthias Schmidt, Andreas Pfestroff, Ulf Lützen, Vikas Prasad, Alexander Heinzel, Martin Heuschkel, Juri Ruf, Peter Bartenstein, Bernd J. Krause

Division of Nuclear Medicine

Research output: Contribution to journal › Article › peer-review

90 Scopus citations

Abstract

Radioligand therapy (RLT) using ¹⁷⁷Lu labelled inhibitors of the prostate-specific membrane antigen (¹⁷⁷Lu-PSMA) is performed in patients with metastatic castration-resistant prostate cancer (mCRPC) after exhaustion of other options. German University Clinics offer RLT since 2013 on a compassionate use basis. The present consensus document includes recommendations for RLT with ¹⁷⁷Lu-PSMA-617. These consensus statements were developed by an expert panel formed by the German Society of Nuclear Medicine (DGN) in December 2015. Statements include recommendations for indication, baseline tests, therapy protocol, concomitant therapy, dosimetry, and follow-up. Consensus recommendations aim to inform the attending medical staff, standardize ¹⁷⁷Lu-PSMA-617 RLT, and improve quality of individual patient care.

Translated title of the contribution	¹⁷⁷Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer
Original language	German
Pages (from-to)	123-128
Number of pages	6
Journal	NuklearMedizin
Volume	55
Issue number	3
DOIs	https://doi.org/10.1055/s-0037-1616480
State	Published - 2016

Keywords

Consensus
Lutetium
Prostate cancer
PSMA
Radioligand therapy

Access to Document

10.1055/s-0037-1616480

Cite this

Fendler, W. P., Kratochwil, C., Ahmadzadehfar, H., Rahbar, K., Baum, R. P., Schmidt, M., Pfestroff, A., Lützen, U., Prasad, V., Heinzel, A., Heuschkel, M., Ruf, J., Bartenstein, P., & Krause, B. J. (2016). Therapie mit ¹⁷⁷Lu-PSMA-617, Dosimetrie und Nachsorge beim metastasierten kastrations - Resistenten Prostatakarzinom. NuklearMedizin, 55(3), 123-128. https://doi.org/10.1055/s-0037-1616480

@article{65adf7e639954136b9a4487d2f0c2e72,

title = "Therapie mit 177Lu-PSMA-617, Dosimetrie und Nachsorge beim metastasierten kastrations - Resistenten Prostatakarzinom",

abstract = "Radioligand therapy (RLT) using 177Lu labelled inhibitors of the prostate-specific membrane antigen (177Lu-PSMA) is performed in patients with metastatic castration-resistant prostate cancer (mCRPC) after exhaustion of other options. German University Clinics offer RLT since 2013 on a compassionate use basis. The present consensus document includes recommendations for RLT with 177Lu-PSMA-617. These consensus statements were developed by an expert panel formed by the German Society of Nuclear Medicine (DGN) in December 2015. Statements include recommendations for indication, baseline tests, therapy protocol, concomitant therapy, dosimetry, and follow-up. Consensus recommendations aim to inform the attending medical staff, standardize 177Lu-PSMA-617 RLT, and improve quality of individual patient care.",

keywords = "Consensus, Lutetium, Prostate cancer, PSMA, Radioligand therapy",

author = "Fendler, {Wolfgang P.} and Clemens Kratochwil and Hojjat Ahmadzadehfar and Kambiz Rahbar and Baum, {Richard P.} and Matthias Schmidt and Andreas Pfestroff and Ulf L{\"u}tzen and Vikas Prasad and Alexander Heinzel and Martin Heuschkel and Juri Ruf and Peter Bartenstein and Krause, {Bernd J.}",

note = "Publisher Copyright: {\textcopyright} Schattauer 2016.",

year = "2016",

doi = "10.1055/s-0037-1616480",

language = "German",

volume = "55",

pages = "123--128",

journal = "NuklearMedizin",

issn = "0029-5566",

number = "3",

}

Fendler, WP, Kratochwil, C, Ahmadzadehfar, H, Rahbar, K, Baum, RP, Schmidt, M, Pfestroff, A, Lützen, U, Prasad, V, Heinzel, A, Heuschkel, M, Ruf, J, Bartenstein, P & Krause, BJ 2016, 'Therapie mit ¹⁷⁷Lu-PSMA-617, Dosimetrie und Nachsorge beim metastasierten kastrations - Resistenten Prostatakarzinom', NuklearMedizin, vol. 55, no. 3, pp. 123-128. https://doi.org/10.1055/s-0037-1616480

TY - JOUR

T1 - Therapie mit 177Lu-PSMA-617, Dosimetrie und Nachsorge beim metastasierten kastrations - Resistenten Prostatakarzinom

AU - Fendler, Wolfgang P.

AU - Kratochwil, Clemens

AU - Ahmadzadehfar, Hojjat

AU - Rahbar, Kambiz

AU - Baum, Richard P.

AU - Schmidt, Matthias

AU - Pfestroff, Andreas

AU - Lützen, Ulf

AU - Prasad, Vikas

AU - Heinzel, Alexander

AU - Heuschkel, Martin

AU - Ruf, Juri

AU - Bartenstein, Peter

AU - Krause, Bernd J.

N1 - Publisher Copyright: © Schattauer 2016.

PY - 2016

Y1 - 2016

N2 - Radioligand therapy (RLT) using 177Lu labelled inhibitors of the prostate-specific membrane antigen (177Lu-PSMA) is performed in patients with metastatic castration-resistant prostate cancer (mCRPC) after exhaustion of other options. German University Clinics offer RLT since 2013 on a compassionate use basis. The present consensus document includes recommendations for RLT with 177Lu-PSMA-617. These consensus statements were developed by an expert panel formed by the German Society of Nuclear Medicine (DGN) in December 2015. Statements include recommendations for indication, baseline tests, therapy protocol, concomitant therapy, dosimetry, and follow-up. Consensus recommendations aim to inform the attending medical staff, standardize 177Lu-PSMA-617 RLT, and improve quality of individual patient care.

AB - Radioligand therapy (RLT) using 177Lu labelled inhibitors of the prostate-specific membrane antigen (177Lu-PSMA) is performed in patients with metastatic castration-resistant prostate cancer (mCRPC) after exhaustion of other options. German University Clinics offer RLT since 2013 on a compassionate use basis. The present consensus document includes recommendations for RLT with 177Lu-PSMA-617. These consensus statements were developed by an expert panel formed by the German Society of Nuclear Medicine (DGN) in December 2015. Statements include recommendations for indication, baseline tests, therapy protocol, concomitant therapy, dosimetry, and follow-up. Consensus recommendations aim to inform the attending medical staff, standardize 177Lu-PSMA-617 RLT, and improve quality of individual patient care.

KW - Consensus

KW - Lutetium

KW - Prostate cancer

KW - PSMA

KW - Radioligand therapy

UR - http://www.scopus.com/inward/record.url?scp=84976576974&partnerID=8YFLogxK

U2 - 10.1055/s-0037-1616480

DO - 10.1055/s-0037-1616480

M3 - Article

C2 - 27350005

AN - SCOPUS:84976576974

SN - 0029-5566

VL - 55

SP - 123

EP - 128

JO - NuklearMedizin

JF - NuklearMedizin

IS - 3

ER -

Therapie mit ¹⁷⁷Lu-PSMA-617, Dosimetrie und Nachsorge beim metastasierten kastrations - Resistenten Prostatakarzinom

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this